Business Context and Reporting Period
Company: Odyssey Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 8, 2026
Reporting Period: Single event date (September 8, 2026)
Context: The filing discloses the posting of a corporate presentation on the company's investor relations website under Item 7.01 (Regulation FD Disclosure). The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to notify the market of the availability of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported within the text of this filing. The only reported event is the dissemination of a corporate presentation.
Guidance, Outlook, and Risks
Management Commentary: The filing references a corporate presentation (Exhibit 99.1) which likely contains management commentary, but the content of that presentation is not included in the filing text.
Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for purposes of Section 18 of the Exchange Act. It is not deemed incorporated by reference into other filings unless expressly stated.
Risks: No specific risks or contingencies are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the content of the corporate presentation (Exhibit 99.1) posted on the company website at https://investors.odysseytx.com/news-events/presentations.
- Confirm the trading symbol (ODTX) and exchange (The Nasdaq Stock Market) for the common stock.
- Note that the presentation is not "filed" for liability purposes under Section 18 of the Exchange Act.
- Check subsequent filings for any financial data referenced in the presentation.